title: Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine.
abstract: In this issue of Blood, Yang et al have demonstrated that the therapeutic activity of a targeted therapy, the tyrosine kinase inhibitor (TKI) dasatinib, unexpectedly depends on antitumor T-cell responses that are strongly potentiated by immunostimulation (agonist anti-OX40).
authors.affiliation: Centre de Recherche en Cancérologie de Lyon.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Marabelle
authors.forename: Christophe
authors.initials: C
authors.lastname: Caux
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D000069439:Dasatinib; D034801:Mastocytoma / Q000188:drug therapy*; D011743:Pyrimidines / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D000906:Antibodies; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib